It is chasing after Vertex Pharma’s VX-548 ... Surveyor Capital, Medicxi, Logos Capital, Octagon Capital, Piper Heartland Healthcare Capital, and LifeSci Venture Partners, along with existing ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

The stock's rise snapped a three-day losing streak.

Jim Cramer continues to show his support for the biotech company, as evident by his most recent comments from the 14 th of ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.